STOCK TITAN

Cosmos Health to Resume Share Repurchases as Insiders Commit to 12-Month Lock-Up

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
buybacks

Cosmos Health (COSM) intends to resume open-market share repurchases, and its executive officers and directors have agreed to a 12-month lock-up.

Approximately $3.85 million remains available under the $5.0 million buyback program the board authorized on June 26, 2026. Cosmos Health has repurchased 255,600 shares (5,112,000 pre-split) for approximately $1.15 million. Future purchases depend on market conditions and other factors. The lock-up bars the officers and directors from selling or otherwise disposing of any common shares they hold.

Loading...
Loading translation...
3 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point. Forward-looking: it has not happened yet and may not happen.Open-market buybacks are planned to resume, with approximately $3.85 million available under the $5.0 million program 26% of market cap
  • Minor point12-month lock-up covers all common shares held by executive officers and directors
  • Minor pointCompleted buybacks total 255,600 shares (5,112,000 pre-split) for approximately $1.15 million

Negative

  • None.

Key Figures

Repurchase program authorization: $5.0 million Shares repurchased to date: 255,600 shares (5,112,000 pre-split) Repurchase spending to date: approximately $1.15 million +2 more
Repurchase program authorization
$5.0 million
Program under which the Company intends to resume open-market repurchases
Shares repurchased to date
255,600 shares (5,112,000 pre-split)
Cumulative repurchases under the program
Repurchase spending to date
approximately $1.15 million
Cumulative spending under the program
Remaining program capacity
approximately $3.85 million
Amount remaining available under the program
Insider lock-up
12 months
Executive officers and directors agreed not to sell or otherwise dispose of shares they hold

Previous Buybacks Reports

1 past event · Latest: Jul 17
Same Type 1 event
  1. Jul 17

    Share repurchases

    24h Move
    -16.4%

    Reported 5.112 million cumulative shares repurchased for approximately $1.11 million under the $5 million program

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rule 10b-18, good manufacturing practices, lock-up
3 terms
rule 10b-18 regulatory
"including Rule 10b-18 under the Securities Exchange Act of 1934"
Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.
good manufacturing practices regulatory
"licensed under European Good Manufacturing Practices (GMP)"
Good manufacturing practices are a set of required processes, controls and documentation that ensure products are made consistently, safely and to quality standards — like following a precise recipe in a clean kitchen so every batch turns out the same. For investors, compliance matters because it affects a maker’s ability to get regulatory approval, avoid costly recalls or production stoppages, and maintain customer and market trust, all of which influence revenue and risk.
lock-up financial
"have agreed not to sell or otherwise dispose of the shares"
A lock-up is an agreement that prevents company insiders, early investors or employees from selling their shares for a set period after a public share offering. It matters to investors because it temporarily limits the number of shares available to trade—like a scheduled hold on extra inventory—and when that hold ends a large number of shares can enter the market, potentially putting downward pressure on the stock price and revealing insiders’ confidence in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CHICAGO, IL / ACCESS Newswire / November 19, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced two shareholder-focused actions: the Company intends to resume open-market repurchases under its $5.0 million share repurchase program, and its executive officers and members of its Board of Directors have agreed to a 12-month lock-up on all shares of the Company's common stock they hold. As a result, the Company intends to repurchase its shares at the same time as its leadership has committed not to sell.

Share Repurchase Program Resumes

The Company intends to resume repurchases under the $5.0 million program authorized by its Board of Directors on June 26, 2026. To date, the Company has repurchased a total of 255,600 shares (5,112,000 pre-split) for approximately $1.15 million, with approximately $3.85 million remaining available under the program.

Repurchases may be made from time to time in the open market, in accordance with applicable securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. The timing and amount of any repurchases will depend on market conditions and other factors, and the program may be suspended or discontinued at any time.

Insiders Commit to a 12-Month Lock-Up

The Company's executive officers and members of its Board of Directors have agreed not to sell or otherwise dispose of the shares of the Company's common stock they hold for a period of 12 months, aligning the interests of the Company's leadership directly with those of its shareholders.

CEO Commentary

Greg Siokas, CEO of Cosmos Health, stated: "We are putting both the Company's capital and our own shares behind our conviction in Cosmos Health. Resuming our buyback and committing our officers and Board to a 12-month lock-up send a clear message: our leadership is invested for the long term. With a strengthened balance sheet, record nine-month revenue and new growth engines, including our expanding subscription model, we believe Cosmos Health is well positioned, and we intend to stand behind that belief."

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

SOURCE: Cosmos Health Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much does Cosmos Health have left for share repurchases?

Cosmos Health has approximately $3.85 million available under its $5.0 million buyback program. The company intends to resume purchases in the open market.

What does the Cosmos Health insider lock-up cover, and how long does it last?

Cosmos Health’s executive officers and directors agreed not to sell or otherwise dispose of any common shares they hold for 12 months.

Keep reading